Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Merck -- Ignore unavailable to you. Want to Upgrade?

To: Sabrejet who wrote (1205)	5/4/1999 2:54:00 PM
From: Racso	Read Replies (1) \| Respond to of 1580

Thread: As of close yesterday, MRK was the most oversold stock (based on relative strength) of both the Dow and the S&P100 indexes. It trades at a current P/E of 28.8 implying a 14.3% discount to the S&P100. This condition cannot continue for too long. Even if the Dow corrects in the days ahead given its own overbought condition, the downside on MRK looks reasonably limited. MRK should start coming back in the next few days in anticipation of the May 23rd FDA ruling on VIOXX.